ABIVAX: Details of Share Capital and Voting Rights as of March 31, 2025

ABIVAX, listed on Euronext Paris under the symbol ABVX, announces its share capital and voting rights figures, updated as of March 31, 2025. The company's share capital amounts to €634,187.49, and is composed of 63,418,749 shares. The total number of theoretical and exercisable voting rights is 71,118,874. These figures are communicated in accordance with Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation.

Theoretical voting rights include all shares, even those without voting rights, while exercisable voting rights do not. ABIVAX is a biotechnology company specializing in the development of treatments for chronic inflammatory diseases, notably with its flagship product, obefazimod, in phase 3 clinical development.